4 results about "Interstitial fibrosis" patented technology

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

The application belongs to the technical field of hydrogel preparation, and particularly relates to a hydrogel loaded with semaglutide and a preparation method and application thereof. The preparation method comprises the following steps: adding ferulic acid modified chitosan into deionized water to obtain a modified chitosan solution, adding oxidized dextran into deionized water, ultrasonic dissolving to obtain an oxidized dextran solution, adding semaglutide into the oxidized dextran solution to obtain an oxidized dextran mixed solution, and mixing the modified chitosan solution and the oxidized dextran mixed solution to obtain the hydrogel loaded with semaglutide. The hydrogel loaded with semaglutide has the advantages of short gelation time, good injection performance, non-toxicity and good biocompatibility. The hydrogel can significantly reduce myocardial interstitial fibrosis after myocardial infarction and improve the ejection capacity of the heart after myocardial infarction. The hydrogel can be used for preparing drugs for treating myocardial infarction.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

The application provides a photobiomodulation method for improving high-sugar-induced human renal tubular epithelial cell damage, the photobiomodulation method comprising the step of treating high-sugar-induced human renal tubular epithelial cells by light irradiation; the light irradiation simultaneously satisfies the following conditions: light irradiation wavelength 530nm-1050nm, energy density 2-10J / cm 2 And power density 10-50mw / cm 2 ; the application also comprises the application of the photobiomodulation method in the preparation of a non-drug intervention product for improving high-sugar-induced renal tubular epithelial cell damage, and in the preparation of a drug or auxiliary treatment instrument for improving diabetic nephropathy; the photobiomodulation method can regulate cell activity, inhibit the level of interstitial fibrosis and related signal pathways, and become a potential treatment method for DKD.